Indocyanine green
OtherIntraoperative perfusion assessment with ICG Fluorescence Angiography (ICG-FA) in standard approved doses
NCT Number: NCT06322862
This is a prospective, multicentre, non-randomized cohort study using real-time intraoperative visualization of bowel perfusion by indocyanine green (ICG) in all-cause bowel ischemia.
At intraoperative finding of bowel ischemia, the initial intraoperative plan is noted and resection margins marked with a steril pen. A fluorescence angiography will be performed and the surgeon will note whether the suspected ischemic bowel is perfused, whether there is a change in the resection margins in centimeters, and if the intraoperative plan has changed. If resection is indicated and the strategy of choice is an anastomosis, a renewed fluorescence angiography will be performed to assess anastomotic perfusion.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Department of Organ Surgery and Transplantation, Copenhagen, Capital Region, Denmark
Fluorescence guided-surgery utilises the fluorescent property of a fluorophore, indocyanine green (ICG), injected intravenously to assess perfusion and viability of the bowel.
This study aims to evaluate the usability and feasibility of ICG to assess bowel viability in an emergency abdominal surgery setting where all-cause bowel ischemia is suspected and intraoperatively present. The investigators aim to evaluate whether ICG fluorescence angiography contributes as an intraoperative aid and changes the intraoperative strategy.
The investigators hypothesize that ICG is a safe and reliable aid in intraoperative decision-making regarding mesenteric ischemia. It may lead to an increasing number of one-step definitive procedures with vital resection margins, primary anastomosis and reducing stomas, and second-look procedures.
In this prospective, non-randomized cohort study bowel viability will be assessed using intraoperative real-time visualization by performing an ICG-fluorescence angiography when there is intraoperative finding of bowel ischemia.
Intraoperatively, ICG (Verdye, Diagnostic Green GmbH 25 mg vials) are dissolved with 5 ml sterile water obtaining a concentration of 5 mg/ml. 0,2mg/kg will be administered intravenously at one to two steps of perfusion assessment.
Initially, the surgeon notes the intended intraoperative plan before fluorescing and if resection is deemed necessary, the resection margins will be marked with a sterile pen.
The perfusion assessment with ICG is then performed and perfusion of the suspected ischemic bowel is noted, along with any change in intended resection margins and intraoperative plan. If an anastomosis is performed, a renewed perfusion assessment is performed. The perfusion assessment will be recorded.
Postoperatively, a subgroup of suitable perfusion assessment recordings will be subject to quantification software using software developed and validated by the investigators (q-ICG).
The trial follows regulations for research in emergency settings and a written and oral informed consent will be obtained from the participant or the participants next of kin and a trial guardian, postoperatively.
Intra- and postoperative clinical data will be collected, including choice of strategy, anastomotic leaks, 30- and 90- day complications, and mortality rates.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intraoperative perfusion assessment with ICG Fluorescence Angiography (ICG-FA) in standard approved doses
Time frame: Assessed at day 30 and 90 after surgery
Change of intraoperative strategy due to ICG fluorescence angiography. Intraoperatively, a nurse will record the initial strategy, indication of resection in centimeters, before and after ICG angiography, and note whether there has been a change in strategy, and how.
Time frame: Assessed at day 30 and 90 after surgery
Number of anastomoses established in ICG-perfused bowel segments
Time frame: 30 months
A posthoc perfusion quantification using q-ICG software
Time frame: Assessed at day 30 and 90 after surgery
Number of cases where stoma was the preferred strategy
Time frame: Assessed at day 30 and 90 after surgery
Number of cases where second-look following bowel discontinuation, was the preferred strategy
Time frame: Assessed at day 30 and 90 after surgery
Cases of anastomotic leaks postoperatively
Time frame: Assessed at day 30 and 90 after surgery
Stratified by type and severity (Comprehensive Complication Index)
Time frame: Assessed at day 30 and 90 after surgery
Stratified by type and severity (Comprehensive Complication Index)
Time frame: 90 days
30- and 90-day mortality rates
Contact information is provided by the study sponsor or research team.
Michael Patrick Achiam, MD, PhD, DMSc
CONTACT
Sermed Ellebæk Nicolae, MD, PhD-student
CONTACT
Rigshospitalet, Denmark
Other
Intraoperative Intestinal Perfusion Assessment by Fluorescence Angiography in Emergency Surgery
Acronym: FLAMES
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04577339
Abdomen, Acute, Abdominal Pain
Portsmouth, Hampshire, United Kingdom
View Trial DetailsNCT07113067
Abulia, Apathy
Charleston, South Carolina, United States
View Trial DetailsNCT05518305
Brain Diseases, Cardiovascular Diseases
Los Angeles, California, United States
View Trial DetailsNCT05393492
Acquired Brain Injury, Brain Diseases
Illkirch-Graffenstaden, France
View Trial Details